Evolution of respiratory syncytial virus genotype BA in Kilifi, Kenya, 15 years on.
Amino Acid Sequence
Biological Evolution
Conserved Sequence
Epidemics
Genetic Variation
Genotype
Glycosylation
Humans
Kenya
/ epidemiology
Markov Chains
Phylogeny
Protein Domains
Respiratory Syncytial Virus Infections
/ epidemiology
Respiratory Syncytial Virus, Human
/ genetics
Viral Proteins
/ chemistry
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 12 2020
03 12 2020
Historique:
received:
07
08
2020
accepted:
20
11
2020
entrez:
4
12
2020
pubmed:
5
12
2020
medline:
17
3
2021
Statut:
epublish
Résumé
Respiratory syncytial virus (RSV) is recognised as a leading cause of severe acute respiratory disease and deaths among infants and vulnerable adults. Clinical RSV isolates can be divided into several known genotypes. RSV genotype BA, characterised by a 60-nucleotide duplication in the G glycoprotein gene, emerged in 1999 and quickly disseminated globally replacing other RSV group B genotypes. Continual molecular epidemiology is critical to understand the evolutionary processes maintaining the success of the BA viruses. We analysed 735 G gene sequences from samples collected from paediatric patients in Kilifi, Kenya, between 2003 and 2017. The virus population comprised of several genetically distinct variants (n = 56) co-circulating within and between epidemics. In addition, there was consistent seasonal fluctuations in relative genetic diversity. Amino acid changes increasingly accumulated over the surveillance period including two residues (N178S and Q180R) that mapped to monoclonal antibody 2D10 epitopes, as well as addition of putative N-glycosylation sequons. Further, switching and toggling of amino acids within and between epidemics was observed. On a global phylogeny, the BA viruses from different countries form geographically isolated clusters suggesting substantial localized variants. This study offers insights into longitudinal population dynamics of a globally endemic RSV genotype within a discrete location.
Identifiants
pubmed: 33273687
doi: 10.1038/s41598-020-78234-0
pii: 10.1038/s41598-020-78234-0
pmc: PMC7712891
doi:
Substances chimiques
Viral Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21176Subventions
Organisme : Wellcome Trust
ID : 102975, 203077
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107769/Z/10/Z
Pays : United Kingdom
Références
Mol Biol Evol. 2008 Jul;25(7):1459-71
pubmed: 18408232
J Virol. 2013 Jul;87(14):8213-26
pubmed: 23698290
Curr Top Microbiol Immunol. 2013;372:83-104
pubmed: 24362685
Vaccine. 2017 Jan 11;35(3):461-468
pubmed: 27692522
PLoS Pathog. 2009 Jan;5(1):e1000254
pubmed: 19119418
Microb Genom. 2019 Sep 18;:
pubmed: 31532357
PLoS One. 2012;7(10):e41953
pubmed: 23077477
J Infect Dis. 2012 Nov 15;206(10):1532-41
pubmed: 22966119
J Infect Dis. 2015 Dec 1;212(11):1711-8
pubmed: 25941331
Virus Evol. 2016 Apr 09;2(1):vew007
pubmed: 27774300
PLoS One. 2012;7(12):e52520
pubmed: 23300695
Clin Infect Dis. 2009 Nov 1;49(9):1341-9
pubmed: 19788358
PLoS One. 2015 Jun 05;10(6):e0129369
pubmed: 26047100
J Virol. 2005 Jul;79(14):9157-67
pubmed: 15994810
J Immunol. 2009 Nov 15;183(10):6338-45
pubmed: 19841167
PLoS Pathog. 2008 Dec;4(12):e1000242
pubmed: 19096508
J Clin Virol. 2017 Mar;88:21-25
pubmed: 28107671
J Virol. 2010 Aug;84(15):7500-12
pubmed: 20504933
Methods Ecol Evol. 2016 Jan;7(1):80-89
pubmed: 27110344
Virus Evol. 2018 Jun 08;4(1):vey016
pubmed: 29942656
Sci Immunol. 2018 Mar 9;3(21):
pubmed: 29523582
Clin Vaccine Immunol. 2016 Jan 27;23(3):186-8
pubmed: 26818954
BMJ. 2019 Sep 10;366:l5021
pubmed: 31506273
Bioinformatics. 2014 Nov 15;30(22):3276-8
pubmed: 25095880
PLoS One. 2011 Mar 01;6(3):e17427
pubmed: 21390255
Clin Infect Dis. 2012 Apr;54 Suppl 2:S190-9
pubmed: 22403235
Clin Infect Dis. 2008 Jan 1;46(1):50-7
pubmed: 18171213
J Infect Dis. 2014 Jun 1;209(11):1685-92
pubmed: 24367040
PLoS Pathog. 2018 Jul 27;14(7):e1007167
pubmed: 30052678
Bioinformatics. 2010 Oct 1;26(19):2455-7
pubmed: 20671151
J Virol. 2016 Apr 29;90(10):4990-5002
pubmed: 26937038
PLoS Pathog. 2018 Mar 6;14(3):e1006935
pubmed: 29509814
J Gen Virol. 1996 Jun;77 ( Pt 6):1249-57
pubmed: 8683213
Vaccine. 2016 Jun 3;34(26):2870-2875
pubmed: 27105562
J Virol. 2015 Aug;89(15):7776-85
pubmed: 25995258
Curr Top Microbiol Immunol. 2013;372:59-82
pubmed: 24362684
Proc Natl Acad Sci U S A. 1987 Aug;84(16):5625-9
pubmed: 2441388
Science. 2009 Oct 30;326(5953):734-6
pubmed: 19900932
J Virol. 2015 Nov;89(22):11630-42
pubmed: 26355091
Rev Med Virol. 2001 Mar-Apr;11(2):103-16
pubmed: 11262529
Virology. 1998 Aug 1;247(2):223-31
pubmed: 9705915
Lancet. 2017 Sep 2;390(10098):946-958
pubmed: 28689664
J Infect Dis. 2004 Nov 15;190(10):1828-32
pubmed: 15499540
Wellcome Open Res. 2018 Jul 25;3:89
pubmed: 30175247
Nat Microbiol. 2019 Jan;4(1):10-19
pubmed: 30546099
AIDS Res Hum Retroviruses. 1995 Oct;11(10):1169-75
pubmed: 8573372
J Virol. 2002 Feb;76(4):1718-30
pubmed: 11799167
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
J Clin Microbiol. 2011 Jun;49(6):2318-20
pubmed: 21490188
Emerg Infect Dis. 2013 Feb;19(2):223-9
pubmed: 23347702
Mol Biol Evol. 2015 Jan;32(1):268-74
pubmed: 25371430
J Infect Dis. 2000 Jun;181(6):1891-6
pubmed: 10837167
JAMA. 2010 May 26;303(20):2051-7
pubmed: 20501927
J Virol. 2015 Aug;89(16):8258-66
pubmed: 26018171
Infect Genet Evol. 2016 Dec;46:200-208
pubmed: 27421210
Annu Rev Virol. 2016 Sep 29;3(1):173-195
pubmed: 27501264
Mol Biol Evol. 2010 Apr;27(4):811-8
pubmed: 19965886
Nat Methods. 2017 Jun;14(6):587-589
pubmed: 28481363
Lancet Glob Health. 2017 Oct;5(10):e984-e991
pubmed: 28911764
J Gen Virol. 2003 Nov;84(Pt 11):3115-3120
pubmed: 14573817
J Virol. 2015 Apr;89(7):3444-54
pubmed: 25609811
J Infect Dis. 2018 Apr 11;217(9):1356-1364
pubmed: 29390105